Cancer Survival Hits Historic 70%: How Immunotherapy Is Rewriting the Odds

For the first time in medical history, seven out of ten people diagnosed with cancer in the United States will survive five years or more. This groundbreaking milestone, announced in the American Cancer Society's 2026 statistics report, represents a transformation from cancer as a death sentence to a manageable chronic condition for millions of Americans.

The five-year relative survival rate has climbed from just 49% in the mid-1970s to 70% during 2015–2021—a dramatic improvement driven largely by advances in immunotherapy, early detection, and targeted treatments. But perhaps most remarkable are the gains for advanced-stage cancers once considered untreatable.

The Numbers Behind the Milestone

The 2026 ACS Cancer Statistics report, published in CA: A Cancer Journal for Clinicians, compiles population-based data from central cancer registries and the National Center for Health Statistics. The findings paint a picture of unprecedented progress alongside persistent challenges.

In 2026 alone, approximately 2,114,850 new cancer cases are projected to be diagnosed in the United States—equivalent to 5,800 diagnoses every day. An estimated 626,140 cancer deaths are expected, representing about 1,720 deaths daily. Despite these sobering figures, the overall cancer mortality rate has declined by 34% from its peak in 1991 through 2023, preventing an estimated 4.8 million deaths.

What makes the survival milestone particularly significant is that improvements are not limited to early-stage disease. For regional-stage cancers, five-year survival increased from 54% in the mid-1990s to 69% during 2015–2021. Even more striking, distant-stage cancer survival doubled from 17% to 35% over the same period.

Immunotherapy: The Game-Changer

While reduced smoking rates and improved screening have contributed to progress, immunotherapy has emerged as the primary driver of survival gains for advanced cancers. These treatments harness the body's immune system to recognize and destroy cancer cells—a fundamental shift from traditional chemotherapy that attacks all rapidly dividing cells.

"Seven in 10 people now survive their cancer five years or more, up from only half in the mid-70s," said Rebecca Siegel, senior scientific director of surveillance research at the American Cancer Society and lead author of the report. "This stunning victory is largely the result of decades of cancer research that provided clinicians with the tools to treat the disease more effectively."

The impact is most visible in cancers that have responded dramatically to immune checkpoint inhibitors—drugs that release the brakes on immune cells, allowing them to attack tumors:

• Metastatic melanoma: Five-year survival jumped from 16% to 35%
• Myeloma: Survival increased from 32% to 62%
• Liver cancer: Improved from 7% to 22%
• Regional lung cancer: Rose from 20% to 37%
• Metastatic lung cancer: Climbed from just 2% to 10%
• Metastatic rectal cancer: Doubled from 8% to 18%

"When we look at metastatic melanoma survival improving from 16% to 35% in just 25 years, we're witnessing the direct impact of immune checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 therapies," said Antoni Ribas, MD, PhD, Professor at UCLA and member of the Cancer Research Institute's Scientific Advisory Council. "These are the breakthroughs that have been championed for decades—supporting the fundamental science that made immunotherapies a reality."

How Immunotherapy Works

Unlike chemotherapy, which directly kills cancer cells but also damages healthy tissue, immunotherapy empowers the patient's own immune system to fight cancer. The most successful approaches include:

Immune Checkpoint Inhibitors: These drugs block proteins like PD-1 and CTLA-4 that cancer cells use to hide from immune detection. By inhibiting these checkpoints, T-cells can recognize and attack tumors more effectively. Since 2011, the FDA has approved more than 150 immunotherapy-related treatments.

CAR-T Cell Therapy: This personalized treatment involves collecting a patient's T-cells, genetically engineering them to target specific cancer markers, and infusing them back into the body. CAR-T has shown remarkable success in blood cancers like leukemia and lymphoma.

Cancer Vaccines: Therapeutic vaccines train the immune system to recognize cancer-specific antigens. Unlike preventive vaccines (like HPV), these treatments aim to eliminate existing tumors.

Bispecific Antibodies: These engineered proteins can bind to both cancer cells and immune cells, bringing them together to enhance destruction of the tumor.

Progress Is Uneven Across Cancer Types

Despite overall improvements, survival rates vary dramatically by cancer type. The highest five-year survival rates are seen in thyroid cancer (nearly 100%), prostate cancer (97%), testicular cancer (95%), and skin cancers (99%). However, some cancers continue to pose significant challenges:

• Pancreatic cancer: Remains at just 13% five-year survival
• Lung cancer: Overall survival is improving but remains low due to late-stage diagnosis
• Liver cancer: At 22%, though this represents a threefold improvement since the mid-1990s
• Esophageal cancer: Survival remains below 20%

"Pancreatic cancer survival remains stagnant at 13%, meaning an estimated 185 Americans diagnosed today face essentially unchanged odds," noted Samik Upadhaya, PhD, in analysis for the Cancer Research Institute. "Uterine corpus cancer mortality continues its 26-year climb."

Geographic and Racial Disparities Persist

The report highlights troubling inequities that undermine overall progress. Cancer death rates vary dramatically across states, ranging from 122 per 100,000 in Utah and Hawaii to 180 per 100,000 in Kentucky—a 48% gap largely driven by lung cancer and smoking prevalence.

Racial and ethnic disparities remain stark:

• Black men have prostate cancer death rates 2–4 times higher than other racial groups
• American Indian and Alaska Native populations face double the mortality rates for kidney, liver, stomach, and cervical cancers compared to White populations
• Black women experience uterine cancer death rates twice as high as White women
• Asian, Black, and Hispanic patients are less likely to receive recommended genetic testing—a critical gateway to targeted therapies

"The largest contributor to survival gaps is reduced access to high-quality care across the cancer continuum, from prevention to diagnosis and treatment," the report states. These disparities are driven by higher prevalence of risk factors, medical mistrust, structural barriers, and lack of insurance coverage.

The Early Detection Gap

Stage at diagnosis remains one of the most critical factors in cancer survival. The report reveals concerning gaps in early detection:

• Only 17% of pancreatic cancers are caught at the localized stage
• Just 28% of lung cancers are diagnosed when localized
• Despite lung cancer screening reducing mortality by up to 24% in high-risk individuals, only about 18% of eligible patients received screening
• Screening rates are even lower among those under 60 (less than 13%) and Native Americans (14%)

For lung cancer specifically, the difference is stark: localized disease has a 65% five-year survival rate compared to just 10% for distant-stage disease. Earlier detection gives immunotherapy its best chance to work effectively.

Rising Rates in Younger Adults

A troubling trend identified in the report is increasing cancer incidence among younger populations:

• Colorectal cancer incidence is rising 2.9% per year in people under 50, even as overall rates declined 0.9% per year over the past decade
• Breast cancer incidence is increasing 1% per year overall since 2013, with an even steeper 1.4% annual increase in women under 50
• In 2026, approximately 200 colorectal cancer diagnoses occur daily in people younger than 65

These trends suggest environmental or lifestyle factors affecting younger generations, though researchers continue to investigate specific causes. Potential contributors include diet, obesity rates, antibiotic use affecting gut microbiome, and environmental exposures.

Challenges Ahead for Cancer Research

The report warns that continued progress faces significant threats:

Funding Uncertainty: Proposed federal cuts to cancer research funding could stall breakthroughs just as momentum builds. "Advances in immunotherapy are the result of decades of investment in foundational scientific research—and future breakthroughs will be impossible without the same long-term commitment," the ACS emphasizes.

Access Barriers: Scientific breakthroughs only save lives if patients can access them. Geographic variation in cancer outcomes reflects differences in prevention programs, screening availability, and quality of care delivery.

Pediatric Cancer Survivorship: While childhood leukemia survival improved from 50% in the mid-1970s to 89% during 2015–2021, long-term effects remain concerning. One in six childhood cancer survivors faces major cardiovascular events by age 50, highlighting the need for gentler, more effective treatments.

Resistant Cancers: Many cancer types remain resistant to current immunotherapies. Only 25–30% of patients typically respond to immunotherapy, making identification of predictive biomarkers and development of combination strategies critical priorities.

What Patients Can Do

While systemic changes are essential, individuals can take steps to improve their cancer outcomes:

1. Know your risk factors: Family history, genetic predispositions, lifestyle factors, and environmental exposures all contribute to cancer risk.

2. Follow screening guidelines: Regular screening for breast, cervical, colorectal, lung (if eligible), and skin cancers can catch disease at treatable stages.

3. Adopt preventive measures: Maintain healthy weight, limit alcohol, avoid tobacco, use sun protection, and get vaccinated against HPV and hepatitis B.

4. Ask about immunotherapy: If diagnosed with cancer, ask your oncologist whether immunotherapy options exist for your specific cancer type and stage.

5. Consider clinical trials: Clinical trials provide access to cutting-edge treatments and contribute to advancing cancer care for future patients.

The Road Forward

The 70% survival milestone represents decades of scientific investment paying dividends. But as William Dahut, MD, chief scientific officer at the American Cancer Society, notes: "We're encouraged by the number of resources to assist millions of survivors, along with the caregivers and families who support them."

The path forward requires sustained commitment to research, equitable access to care, and continued innovation in immunotherapy and precision medicine. With over 1,000 immunotherapy clinical trials currently underway, the next generation of treatments promises to extend survival gains to more cancer types and more patients.

"The immune system holds extraordinary power to fight cancer," said Shane Jacobson, CEO of the American Cancer Society. "Continued research is essential to unlocking that power and extending its promise to patients everywhere."

As we celebrate this historic milestone, the focus must remain on ensuring every patient—regardless of race, geography, or socioeconomic status—has access to the life-saving advances that made 70% survival possible.

---

References

1. Siegel RL, Miller KD, Wallewski JL, et al. Cancer statistics, 2026. CA: A Cancer Journal for Clinicians. 2026;76(1):7-33. DOI: https://doi.org/10.3322/caac.70043. URL: https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.70043

2. American Cancer Society. Cancer Facts & Figures 2026. Atlanta, GA: American Cancer Society; 2026. URL: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf

3. Dutta SS. Cancer mortality drops 34% as treatments and early detection improve. News-Medical. January 16, 2026. URL: https://www.news-medical.net/news/20260116/Cancer-mortality-drops-3425-as-treatments-and-early-detection-improve.aspx

4. Upadhaya S. Cancer in 2026: How Immunotherapy Is Reshaping the Odds. Cancer Research Institute Blog. February 20, 2026. URL: https://www.cancerresearch.org/blog/cancer-statistics-2026

5. Chen A. More people are surviving cancer than ever before, according to new report. STAT News. January 13, 2026. URL: https://www.statnews.com/2026/01/13/why-more-people-survive-cancer-new-report/

6. National Cancer Institute. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute; 2026. URL: https://seer.cancer.gov/csr/

7. Food and Drug Administration. Immunotherapy Approvals. Silver Spring, MD: FDA; 2026. URL: https://www.fda.gov/vaccines-blood-biologics/cancer-cell-therapy-products

8. Cancer Research Institute. CRI Funded Scientists. New York, NY: CRI; 2026. URL: https://www.cancerresearch.org/cri-funded-scientists

---

Disclaimer: This article is for informational purposes only and should not replace professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment of cancer or any medical condition.